CAJ | 학술논문

目的分析神经胶质瘤中缓激肽B2受体表达水平与病理分级的相关关系,为缓激肽及其类似物的临床应用提供实验依据.方法采用神经胶质瘤患者术后标本,用H&E染色进行神经胶质瘤的病理诊断及分级,用免疫组化法和Western Blot法测定不同病理分级的神经胶质瘤中缓激肽B2受体的表达水平.结果H&E染色显示26例神经胶质瘤中Ⅰ级为9例,Ⅱ级为9例,Ⅲ级为8例,Ⅳ级为0例.胶质瘤边缘水肿带不表达缓激肽B2受体,B2受体位于胶质瘤细胞.Western Blot结果显示在三组不同病理分级的神经胶质瘤中,B2受体表达水平为Ⅰ级与Ⅱ级(39480.88±5119.96对51354.25±6168.77,n=8,t=2.447,P＜0.05),Ⅰ级与Ⅲ级(39480.88±5119.96对73032.13±8802.71,n=8,t=7.710,P＜0.001),Ⅱ级与Ⅲ级(51354.25±6168.77对73032.13±8802.71,n=8,t=5.704,P＜0.001);神经胶质瘤中缓激肽B2受体表达水平与其病理分级Ⅰ级～Ⅲ级呈显著正相关(r=0.895,P＜0.001),呈Ⅰ级＜Ⅱ级＜Ⅲ级状况.免疫组化法显示在三组不同病理分级的神经胶质瘤中,B2受体阳性区域面积占切片面积的百分比值为Ⅰ级与Ⅱ级(3.54%±1.51%对8.47%±3.45%,n=8,t=3.698,P＜0.01),Ⅰ级与Ⅲ级(3.54%±1.51%对15.94%±1.68%,n=8,t=15.562,P＜0.001),Ⅱ级与Ⅲ级(8.47%±3.45%对15.94%±1.68%,n=8,t=5.505,P＜0.001);神经胶质瘤中缓激肽B2受体阳性区域面积占切片面积的百分比值与其病理分级Ⅰ级～Ⅲ级呈显著正相关(r=0.878,P＜0.001),呈Ⅰ级＜Ⅱ级＜Ⅲ级状况.结论神经胶质瘤B2受体表达水平与其病理分级Ⅰ级～Ⅲ级呈显著正相关,提示利用缓激肽及其类似物开放血肿瘤屏障的疗效差异可能与B2受体表达水平有关.
목적분석신경효질류중완격태B2수체표체수평여병리분급적상관관계,위완격태급기유사물적림상응용제공실험의거.방법채용신경효질류환자술후표본,용H&E염색진행신경효질류적병리진단급분급,용면역조화법화Western Blot법측정불동병리분급적신경효질류중완격태B2수체적표체수평.결과H&E염색현시26례신경효질류중Ⅰ급위9례,Ⅱ급위9례,Ⅲ급위8례,Ⅳ급위0례.효질류변연수종대불표체완격태B2수체,B2수체위우효질류세포.Western Blot결과현시재삼조불동병리분급적신경효질류중,B2수체표체수평위Ⅰ급여Ⅱ급(39480.88±5119.96대51354.25±6168.77,n=8,t=2.447,P＜0.05),Ⅰ급여Ⅲ급(39480.88±5119.96대73032.13±8802.71,n=8,t=7.710,P＜0.001),Ⅱ급여Ⅲ급(51354.25±6168.77대73032.13±8802.71,n=8,t=5.704,P＜0.001);신경효질류중완격태B2수체표체수평여기병리분급Ⅰ급～Ⅲ급정현저정상관(r=0.895,P＜0.001),정Ⅰ급＜Ⅱ급＜Ⅲ급상황.면역조화법현시재삼조불동병리분급적신경효질류중,B2수체양성구역면적점절편면적적백분비치위Ⅰ급여Ⅱ급(3.54%±1.51%대8.47%±3.45%,n=8,t=3.698,P＜0.01),Ⅰ급여Ⅲ급(3.54%±1.51%대15.94%±1.68%,n=8,t=15.562,P＜0.001),Ⅱ급여Ⅲ급(8.47%±3.45%대15.94%±1.68%,n=8,t=5.505,P＜0.001);신경효질류중완격태B2수체양성구역면적점절편면적적백분비치여기병리분급Ⅰ급～Ⅲ급정현저정상관(r=0.878,P＜0.001),정Ⅰ급＜Ⅱ급＜Ⅲ급상황.결론신경효질류B2수체표체수평여기병리분급Ⅰ급～Ⅲ급정현저정상관,제시이용완격태급기유사물개방혈종류병장적료효차이가능여B2수체표체수평유관.
Objective To analyze the correlation between the expressing level of bradykinin B2receptor and pathological grade of gliomas, and supply experimental basis for clinical application of bradykinin or its analog. Methods The clinicopathologic findings were diagnosed by reviewing all hematoxylin and eosin (H&E) stained tissue sections. To determine the expressing level of bradykinin B2 receptor in glioma, immunohistochemistry and Western blot methods were used.Results Results of H&E staining: In 26 cases of glioma there were 9 cases of grade Ⅰ, 9 cases of grade Ⅱ, 8 cases of grade Ⅲ, and 0 case of grade Ⅳ. Bradykinin B2 receptor localized on tumor cells while the cells of edematous band at the edge of glioma did not express B2 receptor. Results of Western blot: grade Ⅰ and grade Ⅱ (39480.88 ± 5119.96 vs 51354.25 ±6168.77, n = 8, t = 2. 447, P ＜ 0.05); grade Ⅰ and grade Ⅲ (39480.88 ± 5119.96 vs 73032.13 ±8802.71, n = 8, t = 7. 710, P ＜ 0. 001 ); grade Ⅱ and grade Ⅲ (51354.25 ± 6168.77 vs 73032.13 ± 8802.71, n = 8,t = 5. 704, P ＜ 0. 001 ). There was a positive correlation between the expressing level of bradykinin B2 receptor and the the pathological grade of glioma (r =0. 895, P ＜0.001) as grade Ⅰ＜grade Ⅱ＜grade Ⅲ. Results of immunohistochemistry:grade Ⅰ and grade Ⅱ (3.54% 1.51% vs 8.47% ±3.45%, n=8, t=3.698, P＜0.01); grade Ⅰ and grade Ⅲ (3.54%±1.51% vs 15.94% ±1.68%, n=8, t=15.562, P＜0.001); grade Ⅱ and grade Ⅲ (8.47% ±3.45% vs 15.94%± 1.68% , n = 8, t = 5. 505, P ＜ 0. 001 ). There was a positive correlation between the positive position area ratio of bradykinin B2receptor and the pathological grade of glioma (r = 0. 878, P ＜0. 001 ) as grade Ⅰ＜ grade Ⅱ＜ grade Ⅲ. Conclusion There was a positive correlation between the expressing level of bradykinin B2 receptor and the pathological grade of glioma. This may be the reason of the diverse cure effects of the increase of blood-tumor barrier permeability induced by bradykinin and its analog.